Covirix Medical (Unlisted)
COVIRIX Medical is an Australia-based clinical-stage pharmaceutical company, which is repositioning an existing antiviral agent, CVX-20733, as a COVID-19 therapeutic. CVX-20733 has a proven dual-action mechanism and an established safety profile to be delivered in an inhalable form, to prevent and treat the COVID-19 virus irrespective of the variant.
16 June 2025
We spoke with Richard Li, Executive Director of Covirix, about the company's work in reprofiling a drug that seems to be effective in the treatment of Covid-19 infection, and the broader use of that drug in other infectious diseases. Covid is still with us in 2025, highlighting the need for continued development of new antivirals, and with avian influenza potentially a threat to public health Covirix might have a tool here as well.